May 28, 2013
/PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company will have a significant presence at the upcoming American Society of Clinical Oncologists Annual Meeting (ASCO 2013) taking place at the McCormick Convention Center in
May 31-June 4
Rosetta Genomics' Cancer Testing Services will be highlighted in an "Industry Expert Theater Presentation," which is a series of hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies*.
Kenneth A. Berlin
, Rosetta Genomics' President and Chief Executive Officer, and
E. Robert Wassman
, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, will deliver a presentation entitled,
"Application of microRNAs in Oncology Diagnostics,
Saturday, June 1st
in the Oncology Professionals Hall. During this presentation, Dr. Wassman will showcase the Rosetta Cancer Origin Test
) featuring case studies of patients with Cancer of Unknown or Uncertain Primary (CUP) impacted by test results, and data from extensive validation studies utilizing samples from real CUP patients, which demonstrated a high level of concordance with the predictions made by leading CUP centers.
"I am excited to have the opportunity to reinforce the fact that, for physicians, patients, and their families, a diagnosis of Cancer of Unknown Primary in many cases is no longer acceptable. It is not a matter of whether to use microRNA profiling, but when to use it," added Dr. Wassman.
The Company will be featuring its Cancer Testing Services (formally known as the miRview
product line) at Exhibit Booth 2101 beginning
Saturday, June 1st
Monday, June 3rd
5:00 PM Central Time
. Rosetta Genomics will have several company representatives, including medical staff, available to discuss its Cancer Testing Services.
The Company's on-line abstract entitled, "
Observational study of real world clinical performance of microRNA molecular profiling for cancer of unknown primary (CUP),"
will be available for discussion at Rosetta's Exhibit Booth. The study demonstrated a high level of concordance of the Rosetta Cancer Origin Test
with the clinical and/or pathological best final diagnosis. There was strong agreement in over 85% of cases, and clinical utility, as measured by consideration of a shift in therapy or significantly increased decisional certainty for therapy, was observed in approximately 70% of the cases. These data demonstrate that the Rosetta Cancer Origin Test
can make a meaningful difference to clinicians' management of their CUP patients.
"We are delighted to have such a strong presence at ASCO 2013, as it allows us to feature our potentially life-saving cancer diagnostic assays at this premier clinical and scientific meeting for oncologists. We are excited to be hosting our first Exhibit Booth at ASCO 2013 and are particularly pleased to have our Cancer Testing Services featured in an Industry Expert Theater Presentation. These are milestone achievements for Rosetta," stated Mr. Berlin.